Advances in Oral Systemic Treatments for Management of Atopic Dermatitis - Episode 4
Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis
Published on:
Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.
Video content above is prompted by the following:
- Please discuss phase 3 and long-term efficacy (International Global Assessment scores, Eczema Area and Severity Index scores, itch relief) and safety data for abrocitinib and upadacitinib in atopic dermatitis (AD).
- How do the long-term data affect your decision to use oral JAK inhibitors in AD?
- Do you have any safety concerns that have not been addressed by the long-term data so far?
